Q1 2021 RESULTS

For further information on Q1 2021 results and definitions of financial indicators, please refer to the press release issued on April 28, 2021 at:
https://www.sanofi.com/en/investors

Sanofi teams around the world have delivered another strong performance in the first quarter of 2021, powered by our growth drivers and the continued execution of our strategy.

Paul Hudson
Chief Executive Officer, Sanofi

COMPANY SALES & BUSINESS EPS*

Q1 2021 COMPANY SALES*
€8,591M
+2.4% (-4.3%)

Q1 2021 BUSINESS EPS*
€1.61
+15% (+5.2%)

SALES BY GLOBAL BUSINESS UNIT

Vaccines
€915M

Specialty Care
€2,891M

General Medicines
€3,672M

Consumer Healthcare
€1,113M

SALES BY GEOGRAPHY

US
€2,893M

Europe
€2,228M

REST OF THE WORLD
€3,470M

of which:
China €726M
Japan €434M
Brazil €258M
Russia €151M

NEW SOCIAL IMPACT STRATEGY

Strong commitment based on 4 pillars:
Affordable access to medicines
Support to vulnerable communities
Preservation of the environment
Inclusive work place

Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines